MY904 [904] (ATCC® HB-9510)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte  /  Disease: Leukemia

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Disease Leukemia
Strain

Strain:  BALB/c (B cell); BALB/c (myeloma)

Applications
The antibody reacts with granulocytes, monocytes and a subset of large granular lymphocytes.
The antibody can be used to reduce the inflammatory response of leukocytes in vivo.
Derivation
Spleen cells were fused with NS-1 myeloma cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against human inflammatory cells (phagocytic leukocytes); against CD11b
Cellular Products
immunoglobulin; monoclonal antibody; against human inflammatory cells (phagocytic leukocytes); against CD11b
Comments
Animals were immunized with human chronic granulocytic leukemia (CGL) cells.
Spleen cells were fused with NS-1 myeloma cells.
The antibody reacts with granulocytes, monocytes and a subset of large granular lymphocytes.
It inhibits adhesion related functions, but does not block iC3b binding.
The antibody can be used to reduce the inflammatory response of leukocytes in vivo.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
Isotype IgG1
Name of Depositor Univ. Michigan, Dana Farber Cancer Inst.
References

Lucchesi BR, et al. Method of reducing tissue damage at an inflammatory site using a monoclonal antibody. US Patent 4,840,793 dated Jun 20 1989

Dana N, et al. Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies. J. Immunol. 137: 3259-3263, 1986. PubMed: 2430017

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Lucchesi BR, et al. Method of reducing tissue damage at an inflammatory site using a monoclonal antibody. US Patent 4,840,793 dated Jun 20 1989

Dana N, et al. Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies. J. Immunol. 137: 3259-3263, 1986. PubMed: 2430017